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Abstract: Because of the difficulty to exclude possible involvement of nuclear DNA mutations, it has 
been a controversial issue whether pathogenic mutations in mitochondrial DNA (mtDNA) and the 
resultant respiration defects are involved in tumor development. To address this issue, our previous 
study generated transmitochondrial mice (mito-mice-ND613997), which possess the nuclear and mtDNA 
backgrounds derived from C57BL/6J (B6) strain mice except that they carry B6 mtDNA with a G13997A 
mutation in the mt-Nd6 gene. Because aged mito-mice-ND613997 simultaneously showed overproduction 
of reactive oxygen species (ROS) in bone marrow cells and high frequency of lymphoma development, 
current study examined the effects of administrating a ROS scavenger on the frequency of lymphoma 
development. We used N-acetylcysteine (NAC) as a ROS scavenger, and showed that NAC 
administration prevented lymphoma development. Moreover, its administration induced longevity in 
mito-mice-ND613997. The gene expression profiles in bone marrow cells indicated the upregulation 
of the Fasl gene, which can be suppressed by NAC administration. Given that natural-killer (NK) cells 
mediate the apoptosis of various tumor cells via enhanced expression of genes encoding apoptotic 
ligands including Fasl gene, its overexpression would reflect the frequent lymphoma development in 
bone marrow cells. These observations suggest that continuous administration of an antioxidant 
would be an effective therapeutics to prevent lymphoma development enhanced by ROS overproduction.
Key words: antioxidant, lymphoma prevention, mouse mtDNA mutation, ROS overproduction
Introduction
mitochondrial dna (mtdna) mutations that induce 
mitochondrial respiration defects have been proposed to 
be involved in aging and age-associated disorders includ-
ing tumor development [13, 14, 18, 23, 24]. moreover, 
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mitochondrial respiration defects caused by nuclear dna 
mutations and the resultant enhanced glycolysis under 
normoxic conditions, i.e. the warburg effect, are re-
ported to be responsible for tumor development 
[4, 7, 16, 19]. Therefore, it is also possible that mito-
chondrial respiration defects caused by an age-associat-
ed accumulation of mtdna mutations induce the war-
burg effect via compensatory upregulation of aerobic 
glycolysis, resulting in tumor development. in fact, so-
matic mutations were preferentially accumulated in tu-
mor mtdna [6, 10, 21]. However, there has been no 
direct evidence for the involvement of mtdna mutations 
in the warburg effect and in tumor development, because 
of the difficulty to exclude possible involvement of 
nuclear dna mutations in these processes [2].
Our previous studies [1, 11, 12] resolved this issue by 
the use of intercellular mtdna transfer technology be-
tween mouse cells expressing different phenotypes re-
lated to tumors. while mtdna introduced from tumor 
cells into normal cells did not induce tumorigenicity [1], 
mtdna exchange between poorly and highly metastatic 
lung carcinoma cells provided convincing evidence that 
a somatic G13997a mtdna mutation in the mt-Nd6 
gene, which encodes subunit 6 of respiration complex i 
(nadH dehydrogenase), reversibly controls develop-
ment of highly metastatic potentials [11]. in this case, 
the induction of high metastasis was not due to the war-
burg effect, but to overproduction of the reactive oxygen 
species (ROs) [12]. subsequently, G13997a mtdna 
was transferred from highly metastatic carcinoma cells 
into mouse female germ line [26] to examine the effect 
of the G13997a mtdna on tumor-related phenotypes. 
The resultant transmitochondrial mice possessing only 
G13997a mtdna, named mito-mice-nd613997, showed 
high frequently of lymphoma formation with aging [9], 
providing convincing evidence for the involvement of 
the mtdna mutations in tumor development.
Based on these observations, this study examined 
whether continuous administration of an antioxidant 
prevents lymphoma development, and corresponds to an 
effective therapeutics to protect lymphoma development 
in mito-mice-nd613997. we also examined the mecha-
nisms of how ROs induce lymphoma formation in mito-
mice-nd613997.
Materials and Methods
Ethical statement
all animal experiments were performed in accordance 
with protocols approved by the experimental animal 
committee of the university of Tsukuba, Japan.
Mice
Old inbred C57BL/6J Jcl (B6) mice were obtained 
from CLea Japan. mito-mice-nd613997 were generated 
in our previous work [26]. we maintained B6 mice and 
mito-mice-nd613997 sharing a common nuclear dna 
background by repeated backcrossing of their females 
with B6 males. animals were housed in groups of up to 
5 in individually ventilated cages under standard condi-
tions (22°C, 12 h light–dark cycle) receiving food and 
water ad libitum. male mice were used in the experi-
ments, and were monitored everyday for general health 
and signs of tumor burden such as hunched postures, 
ruffled coats and respiratory distress were humanely 
killed. moribund mice were euthanized by cervical dis-
location under general anesthesia (avertin, 1.25%, 
0.2 ml/20 g body weight, intraperitoneally).
NAC administration
at 15 months old, sixteen mito-mice-nd613997 were 
divided at random into two groups. One group was 
given drinking water containing 10 g/l of naC (siG-
ma), and another group was given regular water. naC 
supplemented water and regular water were prepared 
fresh everyday.
Histological analyses
Formalin-fixed, paraffin-embedded serial sections 
(10 µm) were used for histological analyses. Hematox-
ylin-and-eosin–stained sections were used for histo-
pathological analysis to identify tumor tissues. The im-
munohistological analysis was performed with antibody 
to Cd45 to determine whether the tumor tissues origi-
nated from leukocytes, and subsequently with antibodies 
to B220 and Cd3 to determine whether the tumor tissues 
were of B-cell or T-cell origin, respectively. deparaf-
finized slides were boiled for antigen retrieval, then in-
cubated with rat anti-mouse Cd45 (clone 30-F11; Bd 
Biosciences, Cat. no. 550539) at a dilution of 1:200 or 
rat anti-mouse B220 (clone Ra3-6B2; Bd Biosciences, 
Cat. no. 553085) at a dilution of 1:50 or goat anti-mouse 
Cd3 (clone m-20; santa Cruz, Cat. no. sc-1127) at a 
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dilution of 1:50. Biotin-conjugated goat anti-rat igG (Bd 
Biosciences, Cat. no. 559286) and rabbit anti-goat igG 
(Vector Laboratories, Cat. no. Ba-5000) were used as 
secondary antibody at a dilution of 1:50 and 1:500, re-
spectively. detection of Cd45, B220 and Cd3 were 
performed using avidin-biotin complex methodologies 
(Vectastain elite aBC kit, Vector Laboratories) with 
daB staining (anti-ig HRP detection kit, Bd Pharmin-
gen). sections were counterstained with hematoxylin.
PCR array analysis
mice were euthanized after 4-week administration of 
naC and bone marrow cells were isolated from mice 
thighbones and shinbones. Total Rna was extracted by 
isOGen (nippon Gene) from mouse bone marrow cells. 
Rna samples were subjected to dnase i treatment (in-
vitrogen) to eliminate dna contaminants and reverse 
transcribed using Oligo (dT)12–18 primer, 10 mm dnTP 
mix, 0.1 m dTT, Rnase Out Recombinant Ribonuclease 
inhibitor, and superscript ii-Reverse Transcriptase (in-
vitrogen). cdna samples were subjected to Rnase H 
treatment (invitrogen), and applied according to the 
manufacturer’s protocol to a RT2 profiler PCR array 
real-time PCR reaction. Real-time monitoring PCR was 
performed with sYBR Green PCR master mix (Qia-
Gen) and an aBi PRism 7900HT sequence detection 
system (applied Biosystems). mouse Cancer Pathway 
Finder RT2 Profiler PCR Array PAMM-033Z (SABiosci-
ences) was performed to profile the expression of 84 
genes related to the cancer pathway (n=3). The expres-
sion profiling was performed using ΔΔCt methods ac-
cording to manufacturer’s protocols. The relative expres-
sion level for each gene was represented as cycle 
threshold (Ct). normalized expression level was calcu-
lated as ΔCt=Ct (Gene of interest) − Ct (control). The 
average ΔCt from three mice was calculated as the rela-
tive expression level of each gene. differential expres-
sion was calculated as ΔΔCt=Ave ΔCt (sample mice) − 
Ave ΔCt (control mice). Fold change was calculated as 
2-ΔΔCt. The P values are calculated based on a student 
t-test of the replicate 2-ΔCt values for each gene in the 
control group and treatment groups.
Statistical analysis
we analyzed data with the student’s t-test. kaplan-
meier curves were assessed with the log-rank test. Val-
ues with P<0.05 were considered significant.
Results
This study examined the idea that the frequent lym-
phoma development in the aged male mito-mice-
nd613997 could be prevented by the administration of an 
antioxidant, if ROs overproduction is responsible for 
the lymphoma development. since most mito-mice-
nd613997 began to develop lymphoma more than 18 
months after the birth [9], we used 15-month-old males 
for continuous administration of N-acetylcysteine (naC) 
as a ROs scavenger. eight of 16 mito-mice-nd613997 
were treated with naC from 15 months after the birth 
by oral administration based on the procedure reported 
previously [5]. The remaining eight mito-mice-nd613997 
were not treated with naC. seven 15-month-old B6 
males untreated with naC were used as controls.
First, we examined whether the naC treatment would 
affect the frequency of lymphoma development and the 
lifespan. median survival times of naC-treated mito-
mice-nd613997, untreated mito-mice-nd613997 and un-
treated B6 mice were 29.3, 22.5 and 25.8 months, re-
spectively (Figs. 1a and B). No statistical significance 
of median survival times was observed between un-
treated mito-mice-nd613997 and untreated B6 mice 
(Fig.1a). These results are consistent with our previous 
observations [9]. in contrast, naC-treated mito-mice-
nd613997 showed longer survival times than untreated 
mito-mice-nd613997 with statistical significance 
(Fig. 1B), while no statistical significance was present 
between naC-treated mito-mice-nd613997 and untreat-
ed B6 mice (Figs. 1a and B). The median survival times 
of untreated mito-mice-nd613997 with and without 
lymphoma-like abnormalities were 24.5 and 20.5, re-
spectively, and were not different with statistical sig-
nificance (Fig. 1C).
Gross necropsy of all dead or euthanized moribund 
mice showed that three of eight mito-mice-nd613997(38%) 
and one of seven B6 mice (14%) had macroscopic lym-
phoma-like abnormalities, including enlarged spleen, 
liver, and nodular tumors, but none of eight naC-treat-
ed mito-mice-nd613997 had these abnormalities (Table 1). 
Histological analyses of abnormal tissues revealed that 
all were hematopoietic neoplasms and positive for the 
pan-leukocyte marker Cd45 (Table 1 and Fig. 2 ). These 
observations suggest that these hematological neoplasms 
may correspond to lymphoma cells, although current 
study did not examine copy-number variations (CnVs) 
in nuclear genomes to show chromosomal instability [9]. 
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Three tumors were of B-cell origin, expressing the B-cell 
maker B220, while one mito-mouse-nd613997 developed 
T-cell lymphoma staining positive for the T-cell marker 
Cd3 (Table 1). These data indicate that naC administra-
tion is an effective therapeutics to prevent lymphoma 
development caused by ROs overproduction. However, 
further works using more numbers of animals than those 
used in this study are required to confirm this idea.
Table 1. Frequencies of lymphoma development in mice
mouse strains no. of mice no. of mice with tumor
Tissues with tumor Histological analysis
Cell lineage
spleen Liver Lymph node Cd45 B220 Cd3
B6 7 1 + + +  + + - B-cell
mito-mice-nd613997 8 3 + - +  + + - B-cell
+ - -  + - + T-cell
+ + +  + + - B-cell
mito-mice-nd613997 
(naC-treated)
8 0
Fig. 1. kaplan-meier survival curves of mito-micend613997. (a) Comparison of lifespans between B6 mice and mito-
micend613997. median survival times of B6 mice (n=7) and mito-micend613997(n=8) were 25.8 and 22.0 months, 
respectively. (B) Comparison of lifespans of between naC-treated and untreated mito-micend613997. naC admin-
istration was started from 15 months after the birth to the end of their lives. median survival times of mito-
micend613997(n=8) and mito-micend613997 treated with naC (n=8) were 22.0 and 29.3 months, respectively. (C) 
Comparison of lifespans between mito-micend613997 that died with and without detectable lymphoma. median 
survival times of mito-micend613997 with detectable lymphoma (n=3) and mito-micend613997 without detectable 
lymphoma (n=5) were 24.5 and 20.5 months, respectively.
naC PReVenTs LYmPHOma deVeLOPmenT 463
Then, we examined the mechanism of frequent lym-
phoma development, which can be prevented by admin-
istration of an antioxidant to mito-mouse-nd613997. Our 
previous study showed that no tumors other than lym-
phoma were developed, and that ROs were overpro-
duced in bone marrow cells but not in splenocytes [9]. 
it is therefore likely that the ROs overproduction in the 
bone marrow cells of mito-mouse-nd613997 is crucial 
for lymphoma development. Thus, we used bone marrow 
cells to identify genes that would be responsible for fre-
quent lymphoma development in mito-mice-nd613997, 
and compared the expression of the genes related to 
cancer pathway (transformation and tumorigenesis) be-
tween mito-mice-nd613997 and B6 mice using PCR array 
(mouse Cancer Pathway Finder RT2 Profiler PCR Array). 
Because most mito-mice-nd613997 began to develop 
Fig. 2. Histological analyses for identification of lymphoma cells in the liver from mito-miceND613997. (a) Hematoxylin 
and eosin (He) staining of the liver sections from mito-micend613997. He staining of the liver sections was carried 
out to identify tumor-like abnormalities in the liver. Left and right panels represent normal liver and liver with tumor-
like abnormalities, respectively. (B) Histological analysis of serial sections of the liver with tumor-like abnormali-
ties. He, hematoxylin-eosin staining to show tumor formation; Cd45, immunohistochemistry using antibody to 
Cd45 to detect leukocytes; B220, immunohistochemistry using antibody to B220 to detect B cells; Cd3, immuno-
histochemistry using antibody to Cd3 to detect T cells. Because this tissue was stained positively with Cd45 and 
B220, but not with Cd3, the results represent abnormal growth of B cell-lymphoma, but not T cell-lymphoma, in 
the liver. (scale bars, 200 µm).
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lymphoma 18 months after the birth, we used 15-month-
old male mice for this experiment to exclude the influ-
ence of the developed lymphoma cells.
Out of 84 cancer pathway-related genes represented 
on mouse Cancer Pathway Finder RT2 Profiler PCR Ar-
ray (supplemental table 1), only two genes, Fasl and 
Lig4 related to apoptosis and dna repair, respectively, 
were selected as genes being differentially expressed 
between bone marrow cells of B6 and mito-mice-
nd613997(Fig. 3). Then, we examined whether expression 
levels of these genes can be changed to the levels of B6 
mice by administration of naC for 4 weeks to mito-
mice-nd613997. The results showed that Fasl overexpres-
sion in mito-mice-nd613997 was suppressed to B6 levels 
by naC administration, while suppressed expression of 
Lig4 levels did not restore to B6 levels (Fig. 3). These 
results indicated the association of Fasl overexpression 
to frequent development of lymphoma in mito-mice-
nd613997.
Discussion
This study addressed two important issues of whether 
treatment of the mito-mice-nd613997 with an antioxidant 
could be an effective therapeutics to prevent lymphoma 
development mito-mice-nd613997, and how ROs over-
production caused by G13997a mtdna introduced from 
highly metastatic lung carcinoma cells induces lym-
phoma development in mito-mice-nd613997.
Concerning the first issue on the therapeutics of lym-
phoma development, the results in this study showed 
that administration of naC, one of the frequently used 
antioxidants, is very effective to prevent lymphoma de-
velopment in mito-mice-nd613997. Our previous study 
proposed the idea that ROs overproduction, but not 
lactate overproduction, is responsible for frequent de-
velopment of lymphoma in mito-mice-nd613997 with 
G13997a mtdna based on the observations that lym-
phoma was not developed in different mito-mice-COi6589 
that showed lactate overproduction but did not show 
ROs overproduction [9]. if this idea is correct, it can be 
predicted that administration of the antioxidants would 
prevent lymphoma development in mito-mice-nd613997. 
Current study examined this prediction and showed that 
naC administration is effective to prevent lymphoma 
development caused by ROs in mito-mice-nd613997. 
However, further works are required to show that naC 
administration prevents ROs overproduction in bone 
marrow cells of mito-mice-nd613997.
while naC administration prevents lymphoma de-
velopment (Table 1), it also induced longevity in mito-
mice-nd613997 (Fig. 1B). median survival times of B6 
mice, mito-mice-nd613997, and naC-treated mito-mice-
nd613997 were 25.8, 22.0, and 29.3, respectively 
(Figs. 1a and B). The longer median survival times of 
naC-treated mito-mice-nd613997 would not be due to 
the prevention of lymphoma formation by naC admin-
istration, because the median survival times of untreated 
mito-mice-nd613997 with and without lymphoma were 
24.5 and 20.5, respectively, and were not different with 
statistical significance (Fig. 1C). Since it appears to be 
Fig. 3. Cancer related gene expression profiles of bone marrow 
cells. RT2 Profiler mouse cancer pathway finder PCR array 
was performed on bone marrow cells. Two genes of 84 
cancer pathway-related genes, Fasl and Lig4, were dif-
ferentially expressed between bone marrow cells of B6 
mice and mito-mice-nd613997. However, only the Fasl 
gene expression was reversibly regulated to normal levels 
by administration of naC. Values were normalized to a 
pool of housekeeping genes on the array by ΔΔCt and are 
reported as the fold change in gene expression relative to 
healthy B6 bone marrow cells. data are represented as 
mean values with sd (n=3). *, P<0.05.
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controversial whether oxidative stress suppresses lon-
gevity or not [20, 25], we could not at present explain 
why naC administration induced longevity in mito-
mice-nd613997. To examine this issue, we have to carry 
out naC administration not only to mito-mice-nd613997 
but also to B6 mice using more numbers of animals.
Concerning the second issue of how ROs overproduc-
tion caused by G13997a mtdna induced lymphoma 
development, this study showed that overexpression of 
Fasl is related the process, because its overexpression 
in mito-mice-nd613997 was suppressed to normal levels 
by naC administration (Fig. 3). Given that natural-
killer (nk) cells mediate the apoptosis of various tumor 
cells via the expression of genes encoding tumor necro-
sis factor-family ligands including the Fasl gene [22], it 
would not be conceivable that its overexpression is re-
sponsible for lymphoma development. Probably, over-
expression of the Fasl gene in NK cells simply reflects 
the progress of the frequent lymphoma development in 
bone marrow cells of mito-mice-nd613997. Therefore, 
we could not at present explain the mechanisms of how 
ROs overproduction induces frequent lymphoma devel-
opment in aged mito-mice-nd613997.
Then, a question is why mito-mice-nd613997 prefer-
entially develop lymphoma [9] (Table 1), even though 
ROs induces various types of cellular damages, leading 
to genomic instability that can result in the development 
of various types of tumors [15]. One answer to this ques-
tion would be that nuclear genetic background of B6 
strain we used for generation of mito-mice-nd613997 is 
prone to develop lymphoma [3, 8, 17]. Based on these 
observations, we would like to propose an idea that 
G13997a mtdna alone would not induce lymphoma 
development in the absence of B6 nuclear genetic back-
ground. To examine this idea, we are going to generate 
new mito-mice-nd613997 carrying G13997a mtdna but 
carrying different nuclear genetic background derived 
from different mouse strains that are not prone to de-
velop lymphoma by backcrossing female mito-mice-
nd613997 to males from different mouse strains.
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